Free Trial
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Price, News & Analysis

Novozymes A/S logo
$65.98 -1.86 (-2.74%)
As of 03:59 PM Eastern

About Novozymes A/S Stock (OTCMKTS:NVZMY)

Key Stats

Today's Range
$65.65
$66.65
50-Day Range
$67.84
$75.47
52-Week Range
$53.95
$75.99
Volume
20,810 shs
Average Volume
38,300 shs
Market Capitalization
$30.90 billion
P/E Ratio
41.76
Dividend Yield
1.15%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

Novozymes A/S (NSIS-B.CO) - Yahoo Finance
A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
NVZMY Novozymes A/S - Seeking Alpha
Novonesis A/S (NVZMY)
Novonesis price target lowered to DKK 490 from DKK 500 at Barclays
Invitation to the Annual General Meeting
See More Headlines

NVZMY Stock Analysis - Frequently Asked Questions

Novozymes A/S's stock was trading at $56.5399 at the beginning of 2025. Since then, NVZMY shares have increased by 16.7% and is now trading at $65.98.

Novozymes A/S (OTCMKTS:NVZMY) announced its earnings results on Wednesday, January, 31st. The biotechnology company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.47 by $0.11. The biotechnology company had revenue of $664.46 million for the quarter.

The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and others.

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
1/31/2024
Today
7/30/2025
Next Earnings (Estimated)
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
CHEM - SPECIALTY
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Previous Symbol
OTC:NVZMY
CIK
1131345
Employees
10,582
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
42.01
Forward P/E Ratio
36.47
P/E Growth
1.29
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
1.66
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$4.15 billion
Price / Sales
7.49
Cash Flow
$1.81 per share
Price / Cash Flow
36.75
Book Value
$25.82 per share
Price / Book
2.57

Miscellaneous

Outstanding Shares
468,300,000
Free Float
N/A
Market Cap
$31.08 billion
Optionable
Not Optionable
Beta
0.91

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (OTCMKTS:NVZMY) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners